A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 in Participants With Relapsed or Refractory T-cell Lymphomas in Japan

• Status: Recruiting
• Trial end date: 2030-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to test the safety, tolerability, efficacy, and drug levels of BMS-986369 in participants with relapsed or refractory T-cell lymphomas in Japan.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bristol-Myers Squibb

Criteria

Inclusion Criteria:

• Have T-cell Lymphoma with relapsed or refractory disease, as assessed by the investigator

• Phase 1 participants must not be responsive, intolerant, or ineligible to standard therapies that may prolong life or provide symptomatic relief, or for whom no standard therapeutic option is available in the clinical practice guidelines in the opinion of the investigator.

• Phase 2 participants must have been treated by at least 1 prior line of systemic therapy.

• Have an Eastern Cooperative Oncology Group performance status of 0, 1 or 2.

Exclusion Criteria:

• Have any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the participants from participating in the study.

• Have any condition, including active or uncontrolled infection, or the presence of laboratory abnormalities, which places the participants at unacceptable risk if he/she were to participate in the study.

• Have a life expectancy ≤ 3 months.

Note: Other protocol-defined inclusion/exclusion criteria apply